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Abstract 
 Proof of concept experiments on an novel ultrasonic diagnostic and therapeutic agent, phase change nano droplet (PCND), were 
performed. It was found using gel phantoms that PCND works as a cavitation accelerator only when ultrasound pulses which 
trigger the phase change of PCND from liquid to gas are exposed in advance. Another kind of nano droplet that cannot change its 
phase to a gas does not work even in the presence of the trigger. The cavitation induction with the aid of PCND was significant in 
B-mode echography as a brightness enhancement. Such a brightness change was also observed in in vivo experiments on tumor 
baring mice in the presence of systemically administered PCNDs and triggering pulses. Moreover, damages in tumor tissues were 
confirmed at the site of the brightness change. The lack of either a PCND or a phase change ultrasound did not induce any 
brightness change, suggesting the same mechanism as a gel phantom works in living tissues. Our results are promising for use in a 
noble ultrasound therapy system with high selectivity and safety while improving the throughput of current ultrasound tumor 
treatment systems. 
© 2012 The Authors. Published by Elsevier B.V. Selection and/or peer-review under responsibility of Professor Mamoru Mitsuishi 
and Professor Paulo Bartolo 
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1. Introduction 
Microbubbles are well-established contrast agents 
used in ultrasound echography and have mostly been 
used to visualize vascularity.  
  
Recently, they have become promising tools for site-
specific diagnosis and therapy in combination with 
ultrasound. Eliegara et al. first demonstrated targeted 
contrast imaging by attaching ligand molecules onto the 
surface of microbubble contrast agents [1]. In addition to 
diagnostic purposes, microbubbles could possibly be 
used as sensitizers for high intensity focused ultrasound 
(HIFU) therapy, which thermally coagulates diseased 
tissues, because they have been found to enhance the 
ultrasonically-induced temperature rise of tissues [2].  
However, a serious problem arises when using 
microbubbles in that they are too big (several microns in 
diameter) to leak into tissues from the blood vessels 
when intravenously administered. In general, utilizing 
injection to let the drug accumulate at the target and then 
to be washed out from the other sites, typically for more 
than one hour. Due to the relatively low stability of 
microbubbles in bodies compared to other types of drugs 
ever used, there are fewer bubbles that are usable as 
HIFU sensitizers than expected. 
Our approach, enabling the delivery of contrast 
agents into tumor tissues and also usable as therapeutic 
sensitizers, uses phase change nano-droplets (PCND) 
[3,4]. It is known that when water-insoluble chemical 
compounds are dispersed in water as particles, their 
apparent boiling points rise due to a kind of superheating 
phenomena [3]. Such a state is pseudo stable and can 
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change to a more stable state through physical stimulus, 
resulting in a phase change from liquid to gas. The phase 
change induces the volume and radius inflation of 
respectively. Figure 1 shows B-mode images of murine 
tumor tissue before and after an exposure of typical 
phase change ultrasound pulse at a frequency of 5-MHz. 
We aim to administer PCND and then change their 
phase to a gas, and to produce microbubbles only at the 
targets inside the body. The phase change visualizes 
whethe the droplets are delivered to the target, and we 
then can further expose the therapeutic ultrasound, such 
as HIFU for site- -
 generation of microbubbles has advantages 
over administering microbubbles themselves if 
microbubble generation and therapy are performed using 
the same transducer. The visualization procedure of on-
demand microbubbles gives us two important pieces of 
information on ultrasound therapy, 1) that a sufficient 
enough amount of therapy sensitizer accumulates at the 
target, and 2) which site will be treated. Since the focus 
of an ultrasound is not easily predicted before exposure 
in non-homogeneous media like the human body, such 
information is useful for developing safe and effective 
types of ultrasound therapy.  
We have been investigating the effect of PCND on 
HIFU therapy. It was suggested that a PCND with a high 
frequency ultrasound could contribute to lowering the 
required energy for HIFU therapy. In this study, we 
investigated the effect of PCND  in combination of low 
frequency ultrasound on  accelerating the cavitation 
induction in vitro. And further we investigated the 
mechanism that allows the PCND to accelerate the 
cavitation in vitro and confirmed if the induced 
cavitation can damage tumor tissues. 
 
 
 
 
 
 
 
 
Fig. 1. Typical phase change in tumor tissue 
2. Method 
 PCND and phantom preparation 
 
The PCND preparation procedure has been described 
elsewhere [4]. In brief, phosphatidyl coline liposome is 
prepared and the liposome suspension is further 
emulsified using a high level of pressure (20 MPa) in the 
presence of perfluorocarbon (perfluoropentane + 
perfluorohexane) liquids. The size distribution of a 
PCND was measured using a LB-550 (Horiba, Ltd., 
Kyoto, Japan) dynamic light-scattering size analyzer. 
non-phase-change nano droplet (NPCND) was prepared 
by replacing the perfluoropantane and perfluorohexnane 
with pefluorooctane. A gel phantom was prepared using 
basically the same procedure as previously reported [6].  
Experimental setup for ultrasound exposure 
In this study, both the in vitro and in vivo experiments 
were performed using the same setup as shown in Fig. 2. 
A focused ultrasound transducer (1.1 MHz at a diameter 
of 48 mm / F number of 1.0) was submerged in a tank of 
degassed water kept at 37ºC. Gel phantoms with the 
PCND were placed at the focus of the transducer. 
Acoustic signals from the gel phantom were received by 
the focused hydrophone. In vivo experiments were 
carried out using anesthetized CDF1 mice bearing Colon 
26 tumor tissues that were subcutaneously implanted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Experimental setup 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Subharmonic signals from PCND-containing gel phantoms on 
1.1 MHz ultrasound exposure 
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3. Results and Discussion 
To investigate the effect of the PCND on accelerating 
the cavitation induction, we measured the acoustic 
signals after exposing a 1.1-MHz ultrasound (5 MPa 
peak negative pressure with 1000 cycles) to a PCND-
containing gel phantom with and without the exposure of 
an ultrasound for the phase change (microbubble 
generation) of the PCND prior to 1.1-MHz ultrasound. 
As an ultrasound for the phase change, a 3.3-MHz pulse 
at an 8.5-MPa peak negative pressure with the duration 
of 100 cycles was used in this study. 
 Figure 3 shows the signal intensity of the subharmonic 
components, which is an indicator of cavitation, 
obtained during exposure to a 1.1-MHz ultrasound. The 
results using a NPCND are also shown. In the presence 
of the PCND, a subharmonic signal was detected only 
when the phase change ultrasound was exposed. This 
result suggested that the PCND itself does not work as a 
cavitation accelerator, but the resulting microbubbles do. 
The results attained when using a NPCND were received 
with phase change ultrasound yet no subharmonic 
signals were observed. 
 The above results strongly suggest that a PCND works 
as a cavitation accelerator only when and where a phase 
change ultrasound is applied and microbubbles are 
produced. Such a property would lead to a very selective 
and safe type of tumor therapy using an ultrasound. 
Other alternative cavitation accelerators for tumor 
therapy are microbubbles injected as is. Although site-
specific microbubbles have already been developed and 
their accumulation onto particular sites has been 
confirmed, so far, their effects are limited to use for only 
diagnostic purposes, presumably due to the small 
amount of bubbles that accumulate. Non-targeted 
microbubbles lack selectivity and cannot be an 
alternative to a PCND. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Change of gel phantom in B-mode image on 1-MHz 
ultrasound exposure 
 
 Furthermore, either targeted or non-targeted, the 
injected microbubbles will not give information on the 
focus of the therapeutic ultrasound prior to exposure.  
The effect of a PCND used as the cavitation accelerator 
was further investigated from ultrasound diagnostic 
images. Figure 4 shows the B-images of a PCND-
containing gel phantom obtained from the pre and post 
exposure of a 1.1-MHz ultrasound under the same 
conditions as shown in Fig. 3 except the number of 
cycles was increased to 11,000. The exposure was 
performed with and without the advanced exposure for 
the phase change. When using the phase-change 
ultrasound, a clear bright region was created, which was 
roughly that the size of the focal zone of the 1.1-MHz 
ultrasound. However, no changes were observed in the 
absence of the phase-change ultrasound while the same 
1.1 MHz ultrasound intensity followed and the PCND 
existed in the phantom. B-mode images taken for a gel 
phantom containing NPCND were also shown. No 
changes were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Change of tumor tissue in B-mode image on 1-MHz 
ultrasound exposure 
 
 Taking the results in Fig. 4 into consideration, we 
presume that when using a PCND and under advanced 
phase-change ultrasound exposure, a 1.1-MHz 
ultrasound can generate cavitation at 5 MPa that is 
visible in ordinal B-mode ultrasound echography. Also 
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we assume that the non brightness changes in the 
absence of either the PCND or phase-change ultrasound 
did not result from the lack in the delectability in 
cavitation induction, but because no cavitation was
induced.
We then proceeded to the in vivo experiments to study 
whether the above phenomena in vitro also takes place
in bodies. 
Figure 5 shows B-mode image of colon 26 tumor tissue
pre and post ultrasound exposure under the same
conditions as shown in Fig. 4. The ultrasound was
exposed for 10 s. The tumor tissue was subcutaneously
inoculated into a CDF1 mouse. The PCND was
administered through the tail vein at a dose of 10 mg/kg.
The ultrasound was exposed 5 min after the PCND 
injection. Similar to what was shown in Fig. 4, a
significant amount of brightness change was observed
when the phase change ultrasound was applied (Fig. 5a),
and was not observed in the presence of the PCND and 
the absence of phase-change ultrasound (Fig. 5b), and in 
the presence of the NPCND and the phase-change 
ultrasound (Fig. 5c). The tendencies in Fig. 5 were the
same as those in Fig. 4.
The mouse in Fig. 5a was sacrificed immediately after 
the experiment and tissue sample was extracted. A cross
section of the tissue stained with Hematoxilin-Eosin is
shown in Fig. 6. Tissue damage was created at the region
where the brightness changes took place in Fig. 5a. In 
this region, a typical necroses pattern such as deep
staining or the elimination of nuclei was observed.  
This suggests that the above described cavitation 
acceleration of the PCND in combination with the
phase-change ultrasound also takes place in vivo.
Moreover, the visualized cavitation induces tissue
damage in tumors.
We concluded that the in vitro and in vivo results match
well, and thus, our PCND gives us a way to very 
selectively induce cavitation at a low acoustic intensity.
In current HIFU tumor therapy systems, relatively low
throughput and the potential spatial lag between 
predetermined and actual ultrasound foci within targets
are very serious problems and limit their clinical
applications. PCND has a possibility to solve both 
problems. The throughput problem is mainly due to the
for the tissues in the 
ultrasound beam path between each ultrasound exposure.
Due to the low intensity, (less than 100 kW/cm2 in this
study) our system does not seem to require cooling time.
This could result in a faster therapy time than 
conventional HIFU therapy systems. The latter problem 
could be also solved by our system as follows. With
PCNDs and trigger pulses, it would be possible to
visualize the focus of the therapeutic ultrasound prior to
inducing the cavitation by the phase change of the
PCND. If some lags were observed, we could either stop
the procedure or re-arrange the focus.
Although further studies are needed on the biological
activities of PCND such as diagnostic and therapeutic
effects in larger animals or the safety issues of PCND as
a medicine, the combination of PCND and ultrasound is 
very promising as a tool for developing a safe and fast 
ultrasound therapy system.
Figure 6 Cross section of tumor tissue exposed to 1 MHz ultrasound in
the presence of PCND and phase change ultrasound
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